Literature DB >> 6271380

Experimental porphyric neuropathy: a preliminary report.

A A Sima, J C Kennedy, D Blakeslee, D M Robertson.   

Abstract

An experimental model for the study of porphyric neuropathy is presented. Injection of either tetraphenyl-porphinesulfonate (TPPS), hematoporphyrin derivative (HpD), or delta-amino-levulinic acid (ALA) into mice resulted in markedly decreased motor nerve conduction velocity (MNCV). THe MNCV returned to normal within one week following the injection of large doses of ALA, and within three weeks following the injection of close to lethal doses of HpD, but there was no recovery of nerve function within 50 days following injection of substantially smaller doses of TPPS. Ultrastructural examination of motor nerves at various times following TPPS injection revealed the gradual development of structural abnormalities. Ultrastructural examination of the same nerves after a single dose of either ALA or HpD failed to demonstrate any abnormalities. The present observations call for precaution as to the use of TPPS as photosensitizer in human cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271380     DOI: 10.1017/s0317167100042992

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

Review 1.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

2.  Cationic dendritic starch as a vehicle for photodynamic therapy and siRNA co-delivery.

Authors:  Sarah A Engelberth; Nadine Hempel; Magnus Bergkvist
Journal:  J Photochem Photobiol B       Date:  2017-02-20       Impact factor: 6.252

3.  Photodynamic therapy of experimental colonic tumours with 5-aminolevulinic-acid-induced endogenous porphyrins.

Authors:  K Orth; K König; F Genze; A Rück
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  An autopsy case of acute porphyria with a decrease of both uroporphyrinogen I synthetase and ferrochelatase activities.

Authors:  M Yamada; M Kondo; M Tanaka; R Okeda; S Hatakeyama; T Fukui; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

5.  Inhibition of Na+, K+-ATPase activity by delta-aminolevulinic acid.

Authors:  V A Russell; M C Lamm; J J Taljaard
Journal:  Neurochem Res       Date:  1983-11       Impact factor: 3.996

6.  Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence.

Authors:  D X Divaris; J C Kennedy; R H Pottier
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

7.  Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach.

Authors:  C S Loh; A J MacRobert; G Buonaccorsi; N Krasner; S G Bown
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

8.  The effect of tetraphenylporphinesulfonate (TPPS) on muscle end-plates in mice. An ultrastructural and quantitative study.

Authors:  I A Felix; A A Sima
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

9.  Porphyrin synthesis in primary nervous tissue cultures from 10(-3) M delta-aminolaevulinic acid in the presence of melatonin and neuropeptides.

Authors:  I Durkó; A Juhász
Journal:  Neurochem Res       Date:  1986-05       Impact factor: 3.996

10.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  C S Loh; J Bedwell; A J MacRobert; N Krasner; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.